Veraxa Biotech Holding AG (VRXAW) Accumulated Expenses (2024 - 2025)
Veraxa Biotech Holding AG (VRXAW) posted quarterly Accumulated Expenses of $3.3 million for Q4 2025, up 62.71% year-over-year from $2.1 million in Q4 2024, and up 62.71% quarter-over-quarter from $2.1 million in Q4 2024.
Veraxa Biotech Holding AG (VRXAW) Accumulated Expenses (2024 - 2025) Analysis & Trends
Veraxa Biotech Holding AG (VRXAW) has reported Accumulated Expenses for 2 consecutive years, with $3.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Accumulated Expenses rose 62.71% year-over-year to $3.3 million; the TTM figure through Dec 2025 stood at $3.3 million (up 62.71% YoY), while the FY2025 annual figure was $3.3 million, up 62.71% from the prior year.
- Accumulated Expenses climbed to $3.3 million in Q4 2025 per VRXAW's latest filing, from $2.1 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $3.3 million in Q4 2025 and bottomed at $2.1 million in Q4 2024.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.35 Mn |
| Dec 31, 2024 | 2.06 Mn |